Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Stress signaling etches heritable marks on chromatin.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.
Embryonic stem cell lines derived from human blastocysts.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Predictive value of early brain atrophy on response in patients treated with interferon β.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.
The history of the oxazaphosphorine cytostatics.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.

Pages